Bainey KR, Welsh RC, Connolly SJ, et al. - Given that among the participants of the COMPASS trial (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) experiencing chronic coronary syndromes or peripheral arterial disease, a reduction in the primary major adverse cardiovascular event (MACE) outcome of cardiovascular death, myocardial infarction, or stroke as well as mortality was evident as a result of dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice-daily plus aspirin 100 mg once-daily vs aspirin 100 mg once-daily, researchers investigated if this continues to be true in patients with a history of percutaneous coronary intervention (PCI). For this purpose, they performed a pre-specified sub-group analysis from COMPASS, focusing on the results of chronic coronary syndrome patients with or without a previous PCI managed with DPI vs aspirin alone. Experts found that DPI vs aspirin afforded consistent decreases in MACE as well as mortality but with increased major bleeding with or without prior PCI. The observed impacts on MACE and mortality were found to be consistent regardless of time since last PCI among those with prior PCI one- year and beyond.